Latest Advances in Lung Cancer Research

FDA approves osimertinib for advanced EGFR-mutated NSCLC. This targeted therapy extends progression-free survival in patients who’ve undergone chemoradiation, offering new hope for difficult-to-treat lung cancer.

At WCLC, experts highlighted various side effects of lung cancer treatments, emphasizing thyroid, skin, eye, and lung complications. They stressed the importance of early detection and proactive management for better patient outcomes.

Researchers discovered miR-195-5p molecule could slow lung cancer growth by inhibiting CXCL5 gene. Lab tests show promise, offering hope for future treatments against this deadly disease.

Merck halted a lung cancer trial combining vibostolimab with Keytruda due to ineffectiveness and side effects. This setback highlights challenges in developing TIGIT inhibitors for cancer treatment.

CDI scientists publish groundbreaking papers on lung cancer breath test and immune system’s role in fighting diseases. These discoveries could revolutionize cancer detection and treatment, potentially improving patient outcomes.

FDA grants Fast Track status to ABD-147, a new lung cancer treatment. This antibody-drug conjugate, developed by AltruBio, could offer hope for ES-SCLC patients with limited options.

A University of Illinois Chicago study finds a correlation between living in violent neighborhoods and an increased risk of cancer.

China approves Tagrisso combined with chemotherapy as a new first-line treatment option for patients with EGFR-mutated advanced lung cancer.

Imfinzi shows promise in extending survival for patients with extensive-stage small cell lung cancer.

Japan approves Tagrisso with chemotherapy as a new first-line treatment for EGFR-mutated advanced lung cancer.

Lung cancer in never-smokers may respond poorly to immunotherapy due to genetic mutations, suggesting a need for tailored treatments.

Lung cancer screening significantly increases early detection and survival rates for at-risk US veterans, a new study finds.